Current cardiovascular risk management patterns with special focus on lipid lowering in daily practice in Switzerland

European Journal of Preventive Cardiology

Volumn 17, Issue 3, 2010, Pages 363-372

  Jaussi, Andres ^a   Noll, Georg ^b   Meier, Bernhard ^c   Darioli, Roger ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

cardiovascular disease risk factors; cholesterol; coronary heart disease; diabetes mellitus; ezetimibe; goal attainment; hypertension; low density lipoprotein; practice survey; PROCAM score; statins; treatment strategies

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; COMPLICATION; CROSS-SECTIONAL STUDY; DOWN REGULATION; DRUG UTILIZATION; DYSLIPIDEMIAS; FEMALE; GENERAL PRACTICE; HEALTH CARE SURVEY; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIVATE PRACTICE; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SWITZERLAND; TREATMENT OUTCOME; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GOAL ATTAINMENT; HEALTH SURVEY; HIGH RISK PATIENT; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK MANAGEMENT; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DRUG UTILIZATION; DYSLIPIDEMIAS; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPOLIPIDEMIC AGENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRIVATE PRACTICE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SWITZERLAND; TREATMENT OUTCOME;

EID: 77953975105     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328333c1d9     Document Type: Article

References (44)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269–1276.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
3. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310–315.
4. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
5. Christianson TJ, Bryant SC, Weymiller AJ, Smith SA, Montori VM. A pen-and-paper coronary risk estimator for office use with patients with type 2 diabetes. Mayo Clin Proc 2006; 81: 632–636.
6. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease. BMJ 1994; 308: 367–372.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
9. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.
10. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.
11. Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681–689.
12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301–1307.
13. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.
14. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720–732.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
16. Riesen WF, Darioli R, Noseda G, Bertel O, Buser P. Empfehlungen zur Prävention der Atherosklerose. Schweizerische Aerztezeitung 2005; 86: 1355–1361.
17. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):E1–E40.
18. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
19. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13: 776–783.
20. Vanuzzo D, Pilotto L, Ambrosio GB, Pyorala K, Lehto S, De Bacquer D, et al. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. Atherosclerosis 2000; 153: 505–517.
21. Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML. Risk assessment and treatment of dyslipidemia in primary health care. Dan Med Bull 2005; 52: 82–85.
22. Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML. Quality of lipid-lowering therapy in patients with ischaemic heart disease: a registerbased study in 3477 patients. J Intern Med 2004; 255: 367–372.
23. Hunninghake DB. Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. Am J Cardiol 2001; 88: 37K–41K.
24. Guthrie RM. Rising to the challenge of treating high-risk patients. Am J Manag Care 2006; 12 (11 Suppl):S318–S324.
25. Senn M, Favrat B, Vaucher P, Burnier M. Physicians' estimates of the 10 year cardiovascular risk in hypertensive patients: an evaluation in primary care physicians in training. Swiss Med Wkly 2006; 136: 603–608.
26. Silber S, Jarre F, Pittrow D, Klotsche J, Pieper L, Zeiher AM, et al. Cardiovascular risk assessment by primary-care physicians in Germany and its lack of agreement with the Established Risk Scores (DETECT). Med Klin (Munich) 2008; 103: 638–645.
27. Roncaglioni MC, Avanzini F, Roccatagliata D, Monesi L, Tamayo-Benitez D, Tombesi M, et al. How general practitioners perceive and grade the cardiovascular risk of their patients. Eur J Cardiovasc Prev Rehabil 2004; 11: 233–238.
28. Pipilis A, Kaliambakos S, Xenodochidis C, Tsakonas G, Sourlas N, Mallios K. Overestimation and underestimation of cardiovascular risk in clinical practice: usefulness of risk estimation charts. Hellenic J Cardiol 2007; 48: 341–345.
29. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil 2005; 12: 521–529.
30. Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br Med J 2003; 326: 1407–1408. Law MR, Wald NJ, Rudnicka AR. Vasc Med 2003; 8:289–90.
31. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 1994; 48: 305–325.
32. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363: 757–767.
33. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.
34. Fitchett DH, Leiter LA, Goodman SG, Langer A. Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients. Can J Cardiol 2006; 22: 835–839.
35. O'Keefe JH Jr., Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50-70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142–2146.
36. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511.
37. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464–473.
38. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009–2026.
39. Adair G. The Hawthorne effect: a reconsideration of the methodological artifact. J of Appl Psychology 1984; 69: 334–345.
40. Firmann M, Mayor V, Vidal PM, Bochud M, Pecoud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 2008; 8: 6.
41. Kindermann M, Adam O, Werner N, Bohm M. Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO). Clin Res Cardiol 2007; 96: 767–786.
42. Krobot KJ, Yin DD, Alemao E, Steinhagen-Thiessen E. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005; 12: 37–45.
43. Lindgren P, Borgstrom F, Stalhammar J, Alemao E, Yin DD, Jonsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005; 12: 530–534.
44. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003; 24: 1903–1911.